The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as ...
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on ...
The business remains strong, contracts keep flowing, and yet the share price is far lower than it was a year ago. The post ...
Amendment reduces and simplifies royalty structure on Teverelix ® from ~4% to 2% while preserving global rights and IP control The Company is ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
The proposed platform is intended to enhance data-driven decision-making across Medicus’ clinical pipeline by integrating Reliant’s proprietary AI technology with Medicus’ clinical, operational, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results